Merit Medical Systems (NASDAQ:MMSI) Announces Earnings Results, Beats Estimates By $0.11 EPS

Merit Medical Systems (NASDAQ:MMSI) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported $0.93 EPS for the quarter, topping the consensus estimate of $0.82 by $0.11, Zacks reports. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. Merit Medical Systems updated its FY 2025 guidance to 3.580-3.700 EPS.

Merit Medical Systems Stock Performance

NASDAQ MMSI traded down $1.46 during trading hours on Tuesday, hitting $102.05. The company’s stock had a trading volume of 783,463 shares, compared to its average volume of 516,680. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.36 and a quick ratio of 3.82. The company has a market cap of $5.95 billion, a P/E ratio of 50.02, a price-to-earnings-growth ratio of 2.34 and a beta of 0.87. The company’s 50 day simple moving average is $102.66 and its two-hundred day simple moving average is $99.81. Merit Medical Systems has a 12 month low of $70.70 and a 12 month high of $111.45.

Analyst Ratings Changes

A number of brokerages have recently commented on MMSI. Wells Fargo & Company raised Merit Medical Systems from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $103.00 to $120.00 in a research report on Wednesday, December 11th. StockNews.com downgraded Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Piper Sandler reissued an “overweight” rating and issued a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. Robert W. Baird lifted their price target on Merit Medical Systems from $107.00 to $109.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC increased their price objective on shares of Merit Medical Systems from $109.00 to $122.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.80.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.